Core Viewpoint - Xuan Bamboo Biotech-B (2575.HK) experienced a significant stock price increase of 25.19% to HKD 96.9, reaching a market capitalization of over HKD 50 billion, following the announcement of its innovative drug Pyrrolisone (brand name: XuanYueNing®) being included in the National Basic Medical Insurance Drug List for 2025 [1] Group 1 - The stock price has surged 735.34% from its IPO price of HKD 11.6 since its listing on October 15, 2023 [1] - The inclusion of Pyrrolisone in the National Basic Medical Insurance Drug List is set to enhance affordability and accessibility for patients, positively impacting the drug's market promotion and sales growth [1] - The company plans to actively support the implementation of the insurance policy, expand core market access, and enhance patient medication accessibility [1]
港股异动丨轩竹生物大涨25% 股价创上市新高 较发行价已累涨超7倍 市值超500亿！
Ge Long Hui·2025-12-12 06:29